Condition

Metastatic Triple-Negative Breast Carcinoma clinical trials and research

• 17Clinical trials
• 2Countries

Newest Metastatic Triple-Negative Breast Carcinoma clinical trials

All recruiting trials (17)

• Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors

  This trial tests whether adding pidnarulex to trastuzumab deruxtecan is safe and finds the best dose for adults with HER2-positive, HER2-low/ultralow, or other HER2-expressing advanced or metastatic breast and solid tumors.

  Recruiting at 2 sites Phase 1 National Cancer Institute (NCI) · Boston, Massachusetts and 1 other locations · NCT07137416

• STEMVAC vaccine plus chemotherapy for PD-L1 negative metastatic triple-negative breast cancer.

  This trial will try giving the STEMVAC cancer vaccine together with standard chemotherapy to adults with PD‑L1 negative metastatic triple‑negative breast cancer to boost the immune system against the tumor.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07078604

• Antibody-drug conjugates for first- and second-line treatment of metastatic HER2‑negative and triple‑negative breast cancer

  This prospective registry will collect real-world data to see how FDA-approved antibody-drug conjugates work as first- or second-line treatments for adults with metastatic HER2‑negative or triple-negative breast cancer.

  Recruiting at 3 sites University of California, San Francisco · San Francisco, California and 2 other locations · NCT06774027

• High-dose radiation combined with pembrolizumab and chemotherapy for PD-L1 positive metastatic triple-negative breast cancer

  This trial tests whether giving high-dose radiation to a few metastatic sites together with pembrolizumab and chemotherapy helps people with PD-L1 positive metastatic triple-negative breast cancer live longer without their disease getting worse.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT06492759

• Tamoxifen plus pegylated liposomal doxorubicin for advanced triple-negative breast cancer

  This trial tests whether combining tamoxifen with pegylated liposomal doxorubicin can shrink or control metastatic or inoperable locally advanced triple-negative breast cancer in patients with low ER expression and a confirmed TP53 genomic alteration who have had prior therapies.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06434064

• Personalized tumor vaccine with checkpoint inhibitors for triple negative breast cancer

  This phase I trial will test whether a personalized tumor membrane vesicle (TMV) vaccine, given alone or with pembrolizumab or ipilimumab, can boost immune response and help control disease in adults with triple negative breast cancer.

  Recruiting at 4 sites Phase 1 Emory University · Atlanta, Georgia and 3 other locations · NCT06324240

• Combining pembrolizumab with cryoablation for metastatic breast cancer

  This study is testing if combining a drug called pembrolizumab with a freezing treatment can help people with advanced triple negative breast cancer feel better compared to just using the drug alone.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06246968

• Datopotamab deruxtecan for treating breast cancer that has spread to the brain

  This study is testing a new drug called datopotamab deruxtecan to see if it can help people with HER2-negative breast cancer that has spread to the brain.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Miami, Florida and 2 other locations · NCT06176261

• Combining neratinib and ruxolitinib for treating metastatic triple-negative breast cancer

  This study is testing if combining two medications, neratinib and ruxolitinib, can help people with advanced triple-negative breast cancer who have already been treated with chemotherapy.

  Recruiting Early Phase 1 Baylor Research Institute · Dallas, Texas · NCT06008275

• Using blood tests to guide chemotherapy changes in metastatic breast cancer

  This study is testing if using blood tests to track cancer DNA can help doctors change chemotherapy treatments faster for people with metastatic triple-negative breast cancer.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT05770531

• Using propranolol and pembrolizumab to treat resistant triple negative breast cancer

  This study is testing if adding propranolol to pembrolizumab can help people with hard-to-treat triple negative breast cancer respond better to their treatment.

  Recruiting Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT05741164

• Infusion of PD1-positive TILs for advanced triple-negative breast cancer

  This study is testing if infusing a special type of immune cells can help people with advanced triple-negative breast cancer feel better and fight their disease.

  Recruiting at 4 sites Phase 1/2 Fundacio Clinic Barcelona · Barcelona, Barcelona and 3 other locations · NCT05451784

• Combining ZEN003694 and Pembrolizumab with Standard Chemotherapy for Advanced Triple-Negative Breast Cancer

  This study is testing a new combination of a targeted drug and immunotherapy with standard chemotherapy to see if it helps people with advanced triple-negative breast cancer.

  Recruiting at 5 sites Phase 1 National Cancer Institute (NCI) · Boston, Massachusetts and 5 other locations · NCT05422794

• Combining Ivermectin with Balstilimab for Advanced Triple Negative Breast Cancer

  This study is testing whether combining ivermectin with balstilimab or pembrolizumab can help people with advanced triple negative breast cancer by shrinking tumors and improving their quality of life.

  Recruiting Phase 1/2 Cedars-Sinai Medical Center · Los Angeles, California · NCT05318469

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Dendritic cell vaccines and pembrolizumab for treating brain metastasis from breast cancer

  This study is testing a new vaccine combined with an immune therapy to see if it can help people with brain metastasis from triple negative or HER2+ breast cancer fight their cancer better.

  Recruiting at 2 sites Phase 2 Roswell Park Cancer Institute · Tampa, Florida and 2 other locations · NCT04348747

• Combining a personalized vaccine with chemotherapy and immunotherapy for metastatic triple-negative breast cancer

  This study is testing if adding a personalized vaccine to chemotherapy and immunotherapy can help people with metastatic triple-negative breast cancer feel better and improve their treatment outcomes.

  Recruiting at 24 sites Phase 2 National Cancer Institute (NCI) · Orange, California and 29 other locations · NCT03606967

Related topics

Quick answers

How many Metastatic Triple-Negative Breast Carcinoma clinical trials are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in United States (16 trials), Spain (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 1: 4, Phase 1/2: 3, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →